Pharma major Lupin is significantly increasing its focus on biosimilars, aiming for a turnover of nearly $500 million from this segment over the next five years, driven by new product launches and expanded presence in key global markets like the US, Europe, and Japan.
'We recently launched Yesintek in the immunology space.'
'API prices are dragging down margins and impacting our competitive ability.'
After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.
'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'
